Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Neumología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 4
ClinicalTrials.gov
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
INTERVENTIONAL
Inicio: 4 de oct de 2006
ID: NCT00388882
Completado
Fase 3
ClinicalTrials.gov
A LARGE-SCALE TRIAL EVALUATING ADJUVANT CHEMOTHERAPY AFTER CURATIVE RESECTION OF NON-SMALL CELL LUNG CANCER
INTERVENTIONAL
Inicio: 1 de feb de 1995
ID: NCT00002823
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis (DVT) and or Pulmonary Embolism (PE).
INTERVENTIONAL
Inicio: 1 de oct de 2009
ID: NCT00986154
Completado
Fase 3
ClinicalTrials.gov
Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
INTERVENTIONAL
Inicio: 24 de nov de 2020
ID: NCT04590586
Completado
Fase 2
ClinicalTrials.gov
A Phase 2b Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
INTERVENTIONAL
Inicio: 3 de nov de 2016
ID: NCT02878330
Completado
Fase 3
ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).
INTERVENTIONAL
Inicio: 1 de dic de 2002
ID: NCT00144339
Activo, no recluta
ClinicalTrials.gov
Real World Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy Against RSV Illness in Infants
OBSERVATIONAL
Inicio: 26 de ago de 2024
ID: NCT06647654
Completado
Fase 2
ClinicalTrials.gov
A 12-week Phase IIa, Double-blind, Placebo-controlled, Randomized Study to Investigate the Efficacy and Safety of AZD7624 in COPD Patients With a History of Frequent Acute Exacerbations While on Maintenance Therapy
INTERVENTIONAL
Inicio: 28 de oct de 2014
ID: NCT02238483
Completado
Fase 3
ClinicalTrials.gov
Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
INTERVENTIONAL
Inicio: 12 de feb de 2021
ID: NCT04751487
Terminado
Fase 3
ClinicalTrials.gov
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Teva-Sponsored Study in Eosinophilic Asthma
INTERVENTIONAL
Inicio: 1 de jun de 2011
ID: NCT01290887
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Phase 3, Open-label Study to Evaluate Sigvotatug Vedotin Compared With Docetaxel in Adult Participants With Previously Treated Non-small Cell Lung Cancer (Be6A Lung-01)
INTERVENTIONAL
Inicio: 21 de feb de 2024
ID: NCT06012435
Completado
Fase 2
ClinicalTrials.gov
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma
INTERVENTIONAL
Inicio: 1 de jun de 2013
ID: NCT01854047
Completado
Fase 3
ClinicalTrials.gov
Long Term Administration of Inhaled Mannitol in Cystic Fibrosis - A Safety and Efficacy Trial in Adult Cystic Fibrosis Subjects
INTERVENTIONAL
Inicio: 1 de sept de 2014
ID: NCT02134353
Terminado
Fase 4
ClinicalTrials.gov
A Prospective, Multicenter, Single-Arm, Open-Label, Phase 4 Study of the Effects of Selexipag on Right Ventricular Remodeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic Resonance Imaging
INTERVENTIONAL
Inicio: 7 de jul de 2021
ID: NCT04435782
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab Compared With Chemotherapy in Patients With Treatment Naïve Advanced or Recurrent (Stage IIIb Not Amenable for Multimodality Treatment) or Metastatic (Stage IV) Non-Small Cell Lung Cancer Who Are Deemed Unsuitable for Platinum-Containing Therapy
INTERVENTIONAL
Inicio: 11 de sept de 2017
ID: NCT03191786
Completado
Fase 3
ClinicalTrials.gov
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy
INTERVENTIONAL
Inicio: 11 de mar de 2014
ID: NCT02008227
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)
INTERVENTIONAL
Inicio: 6 de dic de 2023
ID: NCT06077760
Desconocido
ClinicalTrials.gov
Extended Compassionate Use Program (UCA) With Inhalational Ibuprofen in Patients With Acute Respiratory Pathology, Mediated by COVID-19.
INTERVENTIONAL
Inicio: 1 de may de 2020
ID: NCT04382768
Completado
Fase 4
ClinicalTrials.gov
A Double-blind, Randomised, Cross-over, Multi-centre Study, to Evaluate Onset of Effect in the Morning in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort®Turbuhaler® 320/9 μg, Compared With Seretide® Diskus® 50/500 μg, Both Given as One Inhalation Twice Daily for One Week Each.
INTERVENTIONAL
Inicio: 1 de sept de 2007
ID: NCT00542880
Completado
Fase 3
ClinicalTrials.gov
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 mcg and 5 mcg Once Daily) Over 12 Weeks as add-on Controller Therapy on Top of Usual Care in Adolescents (12 to 17 Years Old) With Severe Persistent Asthma
INTERVENTIONAL
Inicio: 1 de ene de 2011
ID: NCT01277523
Anterior
1
...
40
41
42
...
434
Siguiente
Filtros